These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38484555)

  • 1. Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3.
    Li G; Liu H; Yu Y; Wang Q; Yang C; Yan Y; Wang F; Mao Y
    EBioMedicine; 2024 Apr; 102():105041. PubMed ID: 38484555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
    Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
    PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer.
    Chang CW; Lee HC; Li LH; Chiang Chiau JS; Wang TE; Chuang WH; Chen MJ; Wang HY; Shih SC; Liu CY; Tsai TH; Chen YJ
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.
    Rubie C; Frick VO; Ghadjar P; Wagner M; Justinger C; Graeber S; Sperling J; Kollmar O; Schilling MK
    World J Gastroenterol; 2011 Jul; 17(26):3109-16. PubMed ID: 21912453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
    Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
    PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.
    Li M; Xia M; Zhang Z; Tan Y; Li E; Guo Z; Fang M; Zhu Y; Hu Z
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35856434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
    Tian S; Wang F; Lu S; Chen G
    Cancer Invest; 2021 Jan; 39(1):62-72. PubMed ID: 33258714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
    Wang D; Yang L; Yu W; Wu Q; Lian J; Li F; Liu S; Li A; He Z; Liu J; Sun Z; Yuan W; Zhang Y
    J Immunother Cancer; 2019 Aug; 7(1):215. PubMed ID: 31395078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
    Sreekumar R; Al-Saihati H; Emaduddin M; Moutasim K; Mellone M; Patel A; Kilic S; Cetin M; Erdemir S; Navio MS; Lopez MA; Curtis N; Yagci T; Primrose JN; Price BD; Berx G; Thomas GJ; Tulchinsky E; Mirnezami A; Sayan AE
    Mol Oncol; 2021 Aug; 15(8):2065-2083. PubMed ID: 33931939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
    Tsai HL; Chen YT; Yeh YS; Huang CW; Ma CJ; Wang JY
    Pathol Oncol Res; 2019 Jul; 25(3):905-913. PubMed ID: 29299827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    Harada K; Okamoto W; Mimaki S; Kawamoto Y; Bando H; Yamashita R; Yuki S; Yoshino T; Komatsu Y; Ohtsu A; Sakamoto N; Tsuchihara K
    BMC Cancer; 2019 Mar; 19(1):255. PubMed ID: 30898102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
    Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
    BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
    Lu W; Fu D; Kong X; Huang Z; Hwang M; Zhu Y; Chen L; Jiang K; Li X; Wu Y; Li J; Yuan Y; Ding K
    Cancer Med; 2020 Feb; 9(4):1419-1429. PubMed ID: 31893575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.
    Deng Y; Wang L; Tan S; Kim GP; Dou R; Chen D; Cai Y; Fu X; Wang L; Zhu J; Wang J
    Mol Oncol; 2015 Aug; 9(7):1341-7. PubMed ID: 25864038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer.
    Ge L; Wang YF; Tian JH; Mao L; Zhang J; Zhang JH; Shen XP; Yang KH
    J Clin Pharm Ther; 2016 Aug; 41(4):383-91. PubMed ID: 27338003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.
    Huang MY; Liu HC; Yen LC; Chang JY; Huang JJ; Wang JY; Lin SR
    Tumour Biol; 2014 Oct; 35(10):9639-47. PubMed ID: 24964961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.